Assessment of global DNA methylation in children with tuberculosis disease

• Main Authors: Kathirvel Maruthai, Ellappan Kalaiarasan, Noyal Mariya Joseph, Subhash Chandra Parija, Subramanian Mahadevan
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2018-01-01
• Series: International Journal of Mycobacteriology
• Subjects: 5-mC quantification; DNA Methylation; hypomethylation; tuberculosis diagnosis; tuberculosis
• Online Access: http://www.ijmyco.org/article.asp?issn=2212-5531;year=2018;volume=7;issue=4;spage=338;epage=342;aulast=Maruthai

Background: Studying DNA methylation changes in disease condition provides the basis of disease pathogenesis or host immune response to infection. Evidences suggest that pathogen-mediated DNA methylation changes influences the expression pattern of genes contributing to disease condition to avert host immune response. Hence, we attempted to study the association between tubercle bacilli-mediated global DNA methylation changes in children with tuberculosis (TB) disease and healthy controls. Methods: Forty-three children diagnosed with TB and 33 healthy children were enrolled in this study. ELISA-based global DNA methylation quantification was performed to measure the changes in percentage of global genomic DNA methylation level. Results: Highly significant difference in global DNA methylation level was found between cases and controls and median global DNA methylation level was 6.25% (interquartile range [IQR] 2.5%–10%) in cases and 25% (IQR, 12.5%–25%) in controls (P < 0.001). Significant difference was found in GeneXpert-positive cases (P < 0.01). Receiver operating curve analysis showed that area under curve 0.81 for the total study population and 0.76 for GeneXpert-positive cases. Conclusion: The results show the significant difference in global DNA methylation level in children with TB disease that can serve as a potential biomarker in early diagnosis of TB disease. Measuring global DNA methylation level, however, not an accurate or sensitive diagnostic method but evaluating active demethylation at genome-wide level can be used to monitor disease progression and treatment efficacy.